Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.43 |
| ▸ | AR | P10275 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533592 | 0.83 | AR (0.40) | EGLN2ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL1815433 | 0.83 | AR (0.40) | EGLN2ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL13216259 | 0.82 | AR (0.44) | EGLN2ARTSHRTRPV4CYP11B1 | |
| SCHEMBL9340535 | 0.80 | EGLN2 (0.40) | EGLN2ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL1196089 | 0.80 | AR (0.43) | ARKDM4EUSP2ALDH1A1TSHR | |
| SCHEMBL223893 | 0.78 | AR (0.42) | EGLN2ARTSHRTRPV4CYP11B1 | |
| SCHEMBL22684010 | 0.78 | TRPV4 (0.38) | EGLN2ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL13199476 | 0.78 | TSHR (0.43) | EGLN2ARKDM4EALDH1A1TSHR | |
| SCHEMBL30432017 | 0.78 | TRPV4 (0.38) | EGLN2ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL2428317 | 0.77 | GRM6 (0.41) | ARKDM4EUSP2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-3660020-B1 | PROCESS FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-11292796-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| CN-106117213-B | Heteroaryl compounds and methods for their synthesis and purification | 西格诺药品有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021209055-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-10-21 | — | — | WO | disclosed |
| US-20200262840-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2020-08-20 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| CN-1939903-A | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | disclosed |
| CN-1939902-A | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | disclosed |
| CN-1894235-A | N-(4-carbamimidoyl-benzyl) -2-alkoxy-2-heterocyclyl acetamides as inhibitors of the formation of coagulation factors xa, ixa and thrombin induced by factor viia | HOFFMANN LA ROCHE (CH) | 2007-01-10 | — | — | CN | disclosed |
| CN-1291975-C | Novel mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | CN | disclosed |
| CN-1656066-A | combination drug | ASTRAZENECA AB (SE) | 2005-08-17 | — | — | CN | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| CN-1487919-A | Novel mandelic acid derivatives and their use as thrombin inhibitors | — | 2004-04-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | EGLN2 2215/4885AR 359/4885KDM4E 2119/4885 |
| US-11292796-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | MTOR, RICTOR, RPTOR | EGLN2 2748/4885AR 634/4885KDM4E 747/4885 |
| US-20200262840-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | EGLN2 2215/4885AR 359/4885KDM4E 2119/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | EGLN2 2153/4885AR 1/4885KDM4E 1539/4885 |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | EGLN2 941/4885AR 1176/4885KDM4E 3146/4885 |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | AR, ESRRA, SHBG | EGLN2 1709/4885AR 1/4885KDM4E 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.